{
    "clinical_study": {
        "@rank": "124203", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1: 5/2 Dosing", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive oral ZSTK474 at a fixed once daily dose administered in 4-week (28-day) cycles of 5 days on drug and 2 days off drug."
            }, 
            {
                "arm_group_label": "Arm 2: 21/7 Dosing", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive oral ZSTK474 at a fixed once daily dose administered in 4-week (28-day) cycles of 21 days on drug and 7 days off drug."
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the safety (adverse events and dose-limiting toxicity) of daily oral doses of\n      ZSTK474 in patients with advanced solid malignancies."
        }, 
        "brief_title": "A Study of ZSTK474 in Japanese Patients With Advanced Solid Malignancies", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Open-label, uncontrolled, serial cohort, dose-escalation study evaluating two different\n      dosing regimens (Arm 1: cycles of 5 days on drug and 2 days off drug), Arm 2: cycles of 21\n      days on drug and 7 days off drug)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Japanese males or females >= 20 years old\n\n          -  Advanced (metastatic or unresectable) solid tumor\n\n          -  ECOG performance status score of 0 or 1 and expected survival >12 weeks\n\n          -  Recovered from hematological toxicities of prior cancer therapies\n\n        Exclusion Criteria:\n\n          -  Previous treatment with PI3K inhibitor\n\n          -  Serious/significant illnesses or underlying conditions, including diabetes or hepatic\n             renal or CV disease.\n\n          -  Other investigational agent within previous 4 weeks\n\n          -  Participating in another clinical study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01682473", 
            "org_study_id": "ZSTK474-201"
        }, 
        "intervention": {
            "arm_group_label": [
                "Arm 1: 5/2 Dosing", 
                "Arm 2: 21/7 Dosing"
            ], 
            "description": "Two arms, each with serial cohorts receiving escalating doses.", 
            "intervention_name": "ZSTK474", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "PI3K inhibitor", 
            "clinical trial"
        ], 
        "lastchanged_date": "March 31, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kashiwa-city", 
                        "country": "Japan", 
                        "state": "Chiba"
                    }, 
                    "name": "National Cancer Center Hospital East"
                }, 
                "investigator": {
                    "last_name": "Toshihiko Doi, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Koto-ku", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }, 
                    "name": "The Cancer Institute Hospital of JFCR"
                }, 
                "investigator": {
                    "last_name": "Shunji Takahashi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of ZSTK474 in Japanese Patients With Advanced Solid Malignancies", 
        "overall_contact": {
            "email": "ZSTK474@mail.zenyaku.co.jp", 
            "last_name": "Morihiro Kanno", 
            "phone": "+81-3-3946-1113"
        }, 
        "overall_official": [
            {
                "affiliation": "National Cancer Center Hospital East", 
                "last_name": "Toshihiko Doi, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "The Cancer Institute Hospital of JFCR", 
                "last_name": "Shunji Takahashi, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants with dose-limiting toxicities", 
            "safety_issue": "Yes", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01682473"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Pharmacokinetics (Cmax, tmax, t\u00bd, AUC)", 
            "safety_issue": "No", 
            "time_frame": "28 days"
        }, 
        "source": "Zenyaku Kogyo Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zenyaku Kogyo Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}